Overview
Public Biotech
Clinical-stage biopharma developing ketamine therapies for suicidal depression. NRX-100 has FDA Fast Track for suicidal ideation. Pursuing $750M generic ketamine market with KETAFREE.
Visit WebsiteWilmington, DE
$35M
Market Cap
2015
Founded
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline
No clinical trials on record